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Abstract 
Assessments of disease progression and response to therapies in Duchenne muscular dystrophy (DMD) patients 
remain challenging. Current DMD patient assessments include complex physical tests and invasive procedures such 
as muscle biopsies, which are not suitable for young children. Defining alternative, less invasive and objective out-
come measures to assess disease progression and response to therapy will aid drug development and clinical trials in 
DMD. In this review we highlight advances in development of non-invasive blood circulating biomarkers as a means 
to assess disease progression and response to therapies in DMD.
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Background
Duchenne muscular dystrophy (DMD) is a severe form 
of myopathy that affects 1 in 5000–20,000 male births 
worldwide [1, 2]. It is due to frame shift mutations in 
the X-linked dystrophin gene abolishing the expres-
sion of the dystrophin protein [3]. Dystrophin connects 
the muscle fiber cytoskeleton to the extracellular matrix 
environment through the dystrophin associated com-
plex (DAPC), a structural complex that protects the sar-
colemma from injuries during muscle fiber contraction 
and relaxation [4, 5]. Absence of dystrophin results in the 
disturbance of the DAPC leading to micro-tears in the 
sarcolemma and calcium influx followed by muscle fiber 
deterioration and tissue inflammation. Clinically, DMD is 
characterized by progressive muscle necrosis and wast-
ing leading to loss of ambulation by 8–12  years of age 
and death by early adulthood due to cardiorespiratory 
failure [6]. Currently there is no cure for the disease only 
treatment to reduce muscle inflammation with glucocor-
ticoids such prednisone and deflazacort. This treatment 
delays loss of ambulation by 1–2 years, but with no long 
term benefit and often accompanied by debilitating side 
effects [7–9]. Recently, multiple drug development pro-
grams focusing on slowing or preventing the progressive 
muscle pathogenesis in DMD have emerged [10]. These 
included therapies aiming to restore expression of the 
missing dystrophin [11–15] and a new corticosteroid dis-
sociative drug with potential for greater anti-inflamma-
tory benefits and fewer side effects [16]. However, lack 
of reliable outcome measures to assess efficacy of these 
drugs had delayed approvals from regulatory agencies. 
So far only the PTC Therapeutics’ Translarna (ataluren) 
drug, a stop codons read through drug, has received 
a conditional approval from the European Medicines 
Agency (EMA) to treat specific group of DMD patients 
with nonsense mutations in the dystrohin gene [17, 18].
Current outcome measures and challenges in DMD
Establishing disease-appropriate outcome measures 
for clinical trials in neuromuscular disorders has been 
challenging. As for any pediatric degenerative disease it 
is critical that outcome measures be specific and sensi-
tive to disease progression and response to treatment. 
However, this becomes a challenge when using a small 
number of pediatric patients and when the therapeutic 
approach may be of high risk and the treatment is admin-
istered for a short period of time.
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Current standardized outcome measures used in DMD 
clinical trials include the 6 min walk (distance patient can 
walk in 6  min) [19], the North Star Ambulatory assess-
ment consisting of number of physical and observational 
test [20], as well as quantitative muscle strength tests 
[21]. However, lack of cooperation in young patients, as 
well as inclusion of ambulant patients only, limits the 
above testing to a subset of the DMD population. Fur-
thermore, it might take longer to observe clinical benefit 
using these physical tests.
Magnetic resonance imaging and T2 mapping are a less 
invasive approach to monitor disease progression and 
response to treatment in DMD patients [22, 23]. While 
these imaging techniques are useful in monitoring mus-
cle loss, cardiac function and other vital parts in DMD 
patients they are often costly, laborious and low through-
put (e.g. 1–2 h machine time per patient).
Molecular biomarkers measured in blood could prove 
valuable to assess disease progression and response 
to therapies in DMD boys. Biomarkers as applied to a 
given disease such as DMD, have utility in one or more 
of the following areas: (1) they are easily accessible and 
less invasive to patients, (2) can act as a diagnostic tool 
(a panel of biomarkers is more specific and reliable than 
a single biomarker); (3) can act as pharmacodynamic 
biomarkers to monitor safety and efficacy of a new treat-
ment; (4) can act as surrogate biomarkers to anticipate 
or predict later clinical benefit of an intervention; (5) can 
inform disease pathophysiological pathways that can lead 
to development of novel therapeutic targets [24].
This review focuses on the latest advances in molecu-
lar biomarker development for DMD with emphasis on 
serum protein biomarkers and their relationship with 
disease progression and response to therapy.
Recent biomarker developments for DMD
Over the past 5 years a series of international meetings 
and workshops have identified the critical need for and 
dissemination of a reliable molecular marker to moni-
tor DMD disease progression and response to treatment 
[25]. This need has become urgent as promising thera-
peutic strategies are entering clinical trials [10]. A cur-
rent challenge in monitoring response to therapies in 
DMD is that different outcome measures are required at 
different stages of the  disease, and these measures can 
sometimes be subjective and lack sensitivity. For exam-
ple, the 6  min walk test, the most common outcome 
measure in DMD clinical trials, can only be applied to 
ambulant DMD patients (≥5 years of age) and requires 
a large cohort and a long time after treatment to 
detect a meaningful outcome. Additionally, very young 
patients (≤4  years of age) and non-ambulant patients 
(≥12 years of age) are often excluded from clinical trials 
due to lack of reliable outcome measures for these spe-
cific age ranges. In this context molecular biomark-
ers are expected to be less subjective, more robust and 
could be implemented throughout disease stages and 
patient ages. Biomarkers could help provide evidence of 
drug efficacy in acute time frames (pharmacodynamic 
biomarkers) as well as predict later clinical outcomes 
(surrogate biomarkers). The need of such biomarkers 
in DMD is further supported by the recent regulatory 
status of eteplirsen (a dystrophin replacement drug for 
DMD) highlighting the importance of dystrophin res-
toration as surrogate biomarker to predict benefit (see 
recent FDA Briefing Document, UCM481911, 2016). 
The importance of accurate measurement of levels of 
restored dystrophin in muscle biopsies and the poor 
precision of Western blot were also highlighted in this 
report and in a review article [26]. In this context our 
laboratory has developed a targeted mass spectrom-
etry assay to accurately quantify dystrophin in muscle 
biopsies [27–29]. The method was found to be highly 
reproducible and linear over wide dynamic range with 
a precision <20  % CV. Dystrophin measurement is an 
ideal outcome measure in clinical trials using dystro-
phin replacement therapies but requires multiples mus-
cle biopsies, which is a burden for pediatric patients. 
Biomarkers accessible in body fluids, on the other hand, 
are less invasive and might prove useful for predicting 
treatment efficacy and outcomes.
Different types of molecular biomarkers have been 
identified in serum, plasma and/or urine of DMD 
patients. These included metabolites, miRNA and pro-
teins. While miRNAs and proteins have been well devel-
oped in the past 5  years, only few studies have been 
published on metabolite biomarkers in DMD [30]. In this 
review we will focus mostly on recent development of 
miRNA and protein as biomarkers for DMD.
Blood circulating miRNAs as biomarkers for DMD
One of the earliest studies investigating miRNA as poten-
tial biomarkers for DMD was based on the potential 
leakge of muscle specific miRNA (dystromiRs) into the 
blood stream of DMD patients [31]. Three miRNA bio-
markers (miR-1, miR-133, and miR-20) were identified 
and found highly elevated in serum of DMD patients and 
patients with Becker’s muscular dystrophy (BMD), a less 
severe form of dystrophinopathy, compared to healthy 
controls. These same miRNAs were also identified as 
elevated in the mdx mouse model for DMD, and their 
levels decreased when dystrophin was restored by exon 
skipping therapy [31]. After this initial study, a series of 
studies conducted in the mdx mouse model and DMD 
patients demonstrated the utility of circulating miRNA 
as biomarkers to monitor disease severity and response 
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to treatments aiming to restore the missing dystrophin 
protein [32–34]. In a recent study, using high-through-
put miRNA sequencing, additional miRNAs including 
cardiomyopathy related miRNAs were identified in the 
golden retriever muscular dystrophy dog model and fur-
ther confirmed in DMD patients [35]. Overall, studies in 
both animal models and patients identified the same set 
of candidate serum circulating miRNAs. This suggests 
the robustness and the specificity of these miRNAs as 
biomarkers for dystrophinopathies. Interestingly, most 
of the elevated circulating miRNAs in serum of DMD 
and mdx mouse model were found unchanged or even 
decreased in muscle tissue.
Serum circulating proteins as biomarkers for DMD
Initial protein biomarker studies in DMD used ELISA 
and other enzyme linked assays to target specific proteins 
based on their relation with muscle damage and pathogen-
esis. These included creatine kinase M (CK-M), a muscle 
specific protein that reflects sarcolemma damage. CK-M 
was reported along ago to be elevated in serum of DMD 
patients relative to controls [36] and it is currently used to 
screen for DMD in newborns [37]. Although CK is a good 
marker to screen for suspected dystrophinopathies it is 
not suitable to monitor disease progression and response 
to  therapy because it decreases sharply with age and its 
concentration is easily influenced by muscle trauma and 
exercise. Although, recent drisapersen trial, have shown the 
utility of CK as a secondary endpoint to assess efficacy [25].
Carbonic anhydrase III (CA-III) and myoglobin are 
other two muscle specific proteins that were targeted for 
analysis by ELISA and were found elevated in blood of 
DMD patients [38, 39]. MMP9, TIMP1 and osteopontin 
are associated with muscle inflammation and were also 
targeted for analysis by ELISA and had altered levels  in 
serum of DMD patients relative to healthy controls [40].
More recently, high throughput “omic” approaches 
were introduced to survey hundreds to thousands of pro-
teins simultaneously in serum samples of DMD patients. 
These techniques confirmed the previously identified bio-
markers, and also uncovered novel markers that are asso-
ciated with muscle pathogenesis and disease progression.
A study by Ayoglu et  al. [41] used an affinity prot-
eomics approach and identified 11 serum protein bio-
markers associated with DMD, of which 5 were novel 
and included myosin light chain-3 (MYL3), troponin T, 
fast skeletal muscle (TNNT3), plastin-2 (LCP1), protein 
phosphatase 1F (PPM1F) and electron transfer flavo-
protein A (ETFA). In this study the authors used bead 
arrays consisting of up to 384 antibodies selected from 
the Human Protein Atlas repository that were directed 
against 315 different proteins and screened a total of 
345 plasma/serum samples from muscular dystrophy 
patients. The method was found to be sensitive with 
highly multiplexing and throughput capabilities.
During the same time period, our lab used two high 
throughput technologies, mass spectrometry based pro-
teomics profiling and SomaScan aptamer array approach 
[42, 43], to query about 1500 unique proteins in serum 
samples of DMD patients. These were performed across 
the age range of DMD patients (4–29  years old). In the 
initial mass spectrometry based proteomics approach 
we queried about 300–400 serum proteins across the age 
range in both DMD patients and two independent mdx 
models for DMD and identified 21 protein biomarkers that 
were concordant between the mouse models studied and 
DMD patients [44]. These biomarkers were mostly of mus-
cle origin and included myofibrillar proteins (titin, myosin 
light chain 1/3, myomesin 3, filamin-C), glycolytic enzymes 
(aldolase, phosphoglycerate mutase 2, beta enolase, and 
glycogen phosphorylase), transport proteins (fatty acid 
binding protein-3, myoglobin and somatic cytochrome-C), 
and others (creatine kinase M, metalloproteinase-9, malate 
dehydrogenase cytosolic and fibrinogen gamma). In the 
second discovery method, we used highly multiplexing and 
high throughput SomaScan aptamer technology to query 
1129 unique proteins in serum of DMD patients (n = 93) 
and age matched healthy volunteers (n =  45) across the 
age range or 4–29 years old. In this second discovery study 
we identified 44 robust serum biomarkers that were con-
cordant between two independent cohorts [45].
Overall using a combination of mass spectrometry based 
proteomics and SomaScan aptamer array we identified 59 
protein biomarkers associated with dystrophin deficiency 
in serum of DMD patients (see Additional file 1: Table S1). 
There were strengths and weaknesses of both platforms. 
The SomaScan required only a small sample volume (65 μl 
per assay), is sensitive, linear over wide dynamic range and 
did not require albumin depletion, but has a poor cover-
age of myofibrillar proteins and other protein fragments 
(e.g. titin, myomesin-3, filamin C, actin skeletal muscle type 
and myosin light chain 1/3). The mass spectrometry based 
proteomics profiling approach is considerably more labor 
intensive and required protein fractionation to separate 
albumin from low abundant proteins, but has detected sev-
eral muscle-derived biomarkers including myofibrillar pro-
teins and other proteins that SomaScan technology did not 
detect because there is no aptamer designed for this class 
of proteins. Nevertheless, Serum proteome profiling using 
SomaScan technology remains superior to mass spectrome-
try based approach in term of sensitivity, dynamic range and 
throughput. Figure 1 shows the overlap and differences in 
the number of biomarkers detected by the two techniques.
In summary, using protein affinity arrays and mass 
spectrometry based proteomics a comprehensive list 
of serum protein biomarkers has been established and 
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is now publically available to researchers in the field of 
muscular dystrophies for data mining and testing (see 
Additional file 1: Table S1).
Circulating biomarkers are indicative of early stage 
muscle damage in DMD boys
We and others have detected fragments of titin protein in 
serum and urine collected from very young DMD patients 
between the age 3 and 4 years old [44, 46, 47]. In our pre-
vious study titin fragments were detected by SDS-PAGE 
based mass spectrometry analysis in the mass range 
between 170 and 240  kDa [44]. These serum circulating 
titin fragments were further confirmed by Western blot 
analysis using titin monoclonal antibody# F146.9B9 from 
Enzo (Fig.  2). The titin fragment abundance decreases 
in older patients (≥10  years old), most likely due to a 
combination of loss of muscle mass and decreased activ-
ity. We hypothesis that the massive Ca2+ influx into 
muscle fibers during the early stage of the disease leads 
to disturbance of calpain activity and subsequent degra-
dation of titin . This hypothesis is further supported by 
detection of N-terminal and C-terminal fragments of titin 
(potential calpain products) in urine samples from DMD 
patients as young as 3  years of age [48]. Furthermore, 
close examination of previously published SomaScan data 
[42] revealed additional markers that were significantly 
altered in their levels in younger DMD boys (~4  years 
of age) compared to age matched controls. As shown in 
Fig. 3, some of the biomarkers associated with DMD are 
already at their highest or lowest level in serum of 4 years 
old DMD boys compared to age matched controls. This 
suggests that muscle damage has already occurred at this 
young age, and perhaps even at birth. However, further 
biomarker studies in DMD infants (1–4  years old) are 
needed to confirm this hypothesis. If this is the case, then 
serum biomarker as an outcome measure would enable 
enrollment of younger DMD patients that have histori-
cally been excluded from clinical trials despite the fact 
that it is widely accepted that earlier treatment may have 
the largest impact on the disease. 
Identified DMD serum protein biomarkers are 
tied to specific pathobiochemical pathways 
and responsive to disease progression and age
Close examination of the protein biomarkers identified in 
the blood of DMD boys revealed four different groups of 
proteins that are tied to specific pathobiochemical path-
ways indicative of muscle fiber leakge, inflammation, 
fibrosis and muscle degeneration/regeneration. Table  1 
summarizes these different groups of proteins and poten-
tial associated pathobiochemical pathways.  
Mass spectrometry based 
proteome profiling assay
13836
SomaScan based proteome 
profiling assay
Fig. 1 Venn diagram showing overlapping and unique number of 
identified biomarkers by SomaScan and mass spectrometry based 
proteome profiling techniques. Both techniques combined identified 
and quantified 59 biomarkers in DMD sera samples. Biomarkers that 
were uniquely identified by mass spectrometry are mostly myofibril-
lar proteins for which there was no Somamer designed. Biomarkers 
that were uniquely identified by SomaScan are those that are below 










4 to 7 yo
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Fig. 2 Western blot showing detection of titin fragment in serum of DMD patients. Titin was detected as a fragment around 170 kDa in serum of 
young DMD patients but very low in serum of older DMD patients and healthy controls. A positive control showing detection of full length titin in 
human muscle extract is also shown. Note that full lenght titin is 3 mega Dalton protein and stayed in the well of the gel
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The first group of biomarkers, reflective of muscle fiber 
leakage, are skeletal muscle derived proteins and includes 
myofibrillar proteins, glycolytic enzymes, Ca2+ regulat-
ing proteins, transport proteins and other muscle specific 
enzymes. These proteins are all localized in the intracellu-
lar compartment of the muscle fiber and the release into 
the blood circulation is reflective of sarcolemma insta-
bility and leakage. These membrane leakage biomarkers 
were all highly elevated at young age (the youngest stud-
ied age was 4 years old) in blood of DMD patients relative 
to age matched healthy controls then gradually decreased 
with age in DMD patients while remained unchanged in 
controls [45], which is similar to CK-M. Figure 4 shows a 
correlation plot and changes in function of age of three 
representative proteins under this category (e.g. CK-M, 
malate dehydrogenase cytosolic (MDHC) and fatty acid 
binding protein-3 (FABP3). The decline in the level of 
these ‘CK–like’ biomarkers as a function of age reflects 
the progressive loss of muscle mass and disease progres-
sion in DMD patient [49] in agreement with earlier stud-
ies comparing levels of CK and pyruvate kinase in DMD 
patients across age [50].
The second group of biomarkers, reflective of fibrosis, 
consisted mostly of proteins involved in extracellular 
matrix remodeling and connective tissue organization. 
This group included hydrolases (e.g. disintegrin and met-
alloproteinase domain-containing protein 9 (ADAM9), 
phospholipase A2 (PLA2G2A), and cell adhesion 
Fig. 3 Representative serum protein biomarkers that are altered in 4 years old DMD boys. CK-M creatine kinase muscle type, CAMK2D calcium/ 
calmodulin-dependent protein kinase type II subunit delta; MK12 mitogen-activated protein kinase 12, RET proto-oncogene tyrosine–protein kinase 
receptor Ret, GDF-11 growth differentiation factor-11; Cadherin-5
Table 1 DMD serum protein biomarkers are tied to specific pathobiochemical pathways
Group Sub-group Pathobiochemical pathway






High levels in young DMD but then decreased 
with age. Unchanged in controls
Proteins involved in connective tissue remod-
eling (n = 14)
Cell adhesion proteins, connective tissue, 
proteases
Maintenance of extracellular matrix integrity
All decreased in DMD versus controls
Inflammatory and immune system (n = 18) Interleukins cytokine, chemokine Inflammation and innate pathway
Some increase with age in DMD
Some decrease with age in DMD
Developmental processes (n = 6) Cell differentiation
Cell proliferation
Muscle regeneration
Decreased with age in DMD while increased with 
age in controls
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proteins (e.g. cadherin-5; CDH5 and cell adhesion mol-
ecule 1; contactin-5). These proteins are localized mostly 
at the cell surface and in the extracellular compartment. 
The majority of cell adhesion proteins were lower in 
blood of DMD patients relative to controls at young age 
and remained lower throughout the age range, reflecting 
connective tissue disorganization. Proteases such met-
alloproteases were elevated in blood of DMD patients 
and might be involved in the extracellular matrix degra-
dation. An example for cadherin 5 (CDH5) is shown in 
Fig. 5.
Third group of biomarkers, reflective of inflammation, 
consisted of 22 proteins involved in inflammatory and 
immune system processes and included mostly cytokines, 
chemokines, complements and interleukins. Some were 
elevated and some were decreased in serum of DMD 
patients compared to controls reflecting the inflamma-
tory state and immune system disturbance in DMD. An 
example for C-X-C motif chemokine 10 (CXCL10) is 
shown in Fig. 5.
Finally the fourth group of biomarkers, reflective of 
muscle degeneration/regeneration, consisted of 6 pro-
teins involved in developmental processes and included 
mostly cell differentiation and cell proliferation factors. 
The majority of these proteins were homeostatic in young 
DMD patients then decreased with age in DMD patients 
while increasing with age in healthy controls, probably 
reflecting the developmental disturbance of the skeletal 
muscle in DMD.
Biomarkers belonging to the last three groups are dis-
similar to CK-M and reflect different pathogenesis pro-
gression of DMD.
Interestingly, some of the biomarkers that were found 
highly elevated in serum of DMD patients and mdx 
mice compared to their respective controls were found 
unchanged in their levels when comparing the proteome 
profiles of dystrophic muscle tissue to normal muscle tis-
sue in the mdx mouse model except for titin, fatty acid 
binding protein 3, lactate dehydrogenase B (LDHB), 
and Troponin I fast skeletal muscle were found slightly 
decreased in dystrophic muscle relative to healthy mus-
cle [51]. The slight decrease of FABP3 and LDHB was 
further confirmed by others in the soleus muscle of mdx 
mice relative to wild type mice [52]. The slight decrease 
of these proteins in muscle tissue and their dramatic 
increase in the blood circulation reflects a high cycles of 
muscle degeneration and regeneration in DMD in both 
human and animal models. Especially at younger age.
Clinical utility of DMD circulating biomarkers
Efforts are under development to test the utility of 
DMD identified serum biomarkers in pre-clinical and 
clinical studies. Ideal biomarkers would enable acute, 




















Fig. 4 Plots showing changes in the serum level of three representa-
tive muscle leakage proteins in function of age in DMD patients. 
Data was generated using SomaScan proteome profiling on serum 
samples collected from 51 DMD patients with age ranging from 4 to 
29 years old. Levels of the three proteins are plotted as relative fluo-
rescent units (RFU) in function of age of DMD patients. CK-M creatine 
kinase muscle type, MDHC malate dehydrogenase cytosolic from, 




































Fig. 5 Plots showing changes in the serum level of two non-CK like 
biomarkers in function of age in DMD patients and healthy controls. 
Data was generated using SomaScan proteome profiling on serum 
samples collected from DMD patients (filled circle) and age matched 
healthy controls (empty circle). A plots is for a subset of DMD patients 
(n = 26) and age matched healthy controls (n = 20). CDH5 cad-
herin-5, CXCL10 C-X-C motif chemokine 10
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biomarkers) and predict later benefit (surrogate bio-
markers). However, to develop such biomarkers a good 
correlation between drug induced changes in the level 
of biomarkers and clinical benefit has to be estab-
lished. A recent study has shown that myomesin-3, a 
membrane leakage biomarker, was sensitive to dystro-
phin replacement therapy in the mdx mouse model for 
DMD [48]. Myomesin-3 levels decreased toward nor-
mal levels in treated mice relative to untreated mice 
with correlation to restored dystrophin levels. Another 
more recent pre-clinical study performed on mdx-23 
mouse model used the highly multiplexing SomaScan 
proteome profiling technology and identified multiple 
biomarkers that responded to dystrophin restoration in 
the mdx mouse model treated with peptide-antisense 
oligonucleotide conjugate [53]. Most of the responsive 
biomarkers were again associated with membrane leak-
age and included phosphoglycerate mutase 1, troponin 
I, Calcium/calmodulindependent protein kinase type II 
subunit beta (Camk2b), cytochrome-c and a disinteg-
rin and metalloproteinase with thrombospondin motifs 
5. Furthermore, several of the biomarkers detected by 
SomaScan technology and were found to be  elevated in 
the serumn of mdx mouse model relative to wild type 
mouse [53] were similar to those detect by the same 
technology to be elevated in DMD patients relative to 
controls [45]. To cite few, these included, CK-M, tro-
ponin-I, myoglobin, FABP3, LDHB, calcium/calmodu-
lin dependent protein kinases, and cytochrome c. But 
few were unique to human samples and this is most 
probably due to the fact that aptamers were optimized 
to recognize human proteins and not mouse proteins. 
Nevertheless this technology can still be used in pre-
clinical settings which will tremendously help test-
ing the response of DMD biomarkers to new drugs in 
animal models. For instance the decrease in myoglo-
bin, FABP3 and cytochrome c identified in mdx mouse 
model treated with PPMO [53] could be tested for their 
utility as pharcodynamic biomarkers to assess response 
to dystrophin replacement therapies in DMD patients.
In summary, several sarcolemma leakage biomarkers 
seem to be sensitive to dystrophin restoration. This sug-
gests that restored (truncated) dystrophin is functional, 
stabilizes the sarcolemma and results in reduced leak-
age of muscle specific proteins into the blood circulation. 
These biomarkers must be validated and qualified for use 
as surrogate biomarkers in future clinical trials. At this 
time it is not known if reduction in biomarker levels is 
dose and time dependent. An ideal surrogate biomarker 
must be sensitive to early effects of the drug and pre-
dict later outcome. To answer these questions a carefully 
designed longitudinal experiment with different drug 
dosing are needed.
It is important to point out that each drug targeting 
specific pathobiochemical pathway in DMD (e.g. sar-
colemma stabilization using dystrophin replacement 
therapies, reduction of muscle inflammation using glu-
cocorticoids and analogue drugs, boosting muscle regen-
eration using growth factors) might affect a specific set of 
blood circulating biomarkers.
A recent study has shown that glucocorticoid treat-
ment correlated with an increase in MMP9 levels in 
DMD patients [54]. However, an earlier study associ-
ated the increase of MMP9 with disease progression 
[40]. Currently there is an ongoing debate whether 
changes in MMP9 is associated with disease progression 
or response to glucocorticoid treatment [55]. But reli-
ance on a single protein might not be ideal to distinguish 
changes due to disease progression or from a drug effect. 
In the list of DMD biomarkers we and others identified 
including miRNAs [31, 35, 41, 44–46] there is a large 
menu of biomarkers associated with different pathobio-
chemical pathways of muscle pathogenesis and disease 
stage. We believe a panel of biomarkers, rather than 
single biomarker, will allow better assessment of a drug 
effect. Furthermore, some drugs such as glucocorticoids 
might affect more than one pathobiochemical pathway 
to enhance muscle function as shown in a recent study 
conducted with low dose glucocorticoids in healthy sub-
jects and mdx mouse model for DMD [56]. This further 
suggests the utility of a panel of biomarkers which might 
reflect the different pathways affected by a drug.
Conclusions
Development of “omic” technologies has enabled discov-
ery of novel biomarkers associated with DMD disease 
progression and response to therapies. Similar studies 
could be performed for a number of pediatric diseases 
that are in need of blood accessible molecular biomarkers 
to monitor disease progression and response to therapies. 
Defining robust and reliable serum pharmacodynamic 
biomarkers to monitor treatment in pediatric population 
will have an impact at several levels: (1) non-invasive and 
will minimize patient burden; (2) less subjective and can 
be used in most clinical trials; (3) Cost effective and will 
aid drug development programs.
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